Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD

Blood (2019) 134 (Supplement_1): 764.

https://doi.org/10.1182/blood-2019-124750

Published: 2019

Journal Articles

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Chloe Yang, MD BS, Haiyan Jiang, PhD, Esther Masih-Khan, PhD, Christine I Chen, MD FRCP(C), Anca Prica, MD FRCP(C), Donna Reece, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3462.

https://doi.org/10.1182/blood.V130.Suppl_1.3462.3462

Published: 2017

Journal Articles

Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Krina K. Patel, MDMSc, Jatin J. Shah, MD, Lei Feng, MS, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Sheeba K. Thomas, MD, Donna M. Weber, MD, Silvia C. Munoz, RN, Ashley Morphey, RN, Qaiser Bashir, MD MBBS, Muzaffar H. Qazilbash, MD, Robert Z. Orlowski, MD PhD

Blood (2017) 130 (Supplement 1): 437.

https://doi.org/10.1182/blood.V130.Suppl_1.437.437

Published: 2017

Journal Articles

Risk of Non-Melanoma Skin Cancer Following Hematopoietic Cell Transplantation and Voriconazole-Associated Risk

Lawrence F. Kuklinski, BA, Shufeng Li, MS, Margaret R. Karagas, PhD, Bernice Y. Kwong, MD, Wen-Kai Weng, MD PhD

Blood (2016) 128 (22): 2249.

https://doi.org/10.1182/blood.V128.22.2249.2249

Published: 2016

Journal Articles

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Blood (2016) 128 (22): 480.

https://doi.org/10.1182/blood.V128.22.480.480

Published: 2016

Journal Articles

Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients

Blood (2016) 128 (22): 3442.

https://doi.org/10.1182/blood.V128.22.3442.3442

Published: 2016

Journal Articles

Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma

Lauren E. Strelec, BA, Erin Haley, MD, Ellen J. Kim, MD, Alain H. Rook, MD, Nirav N. Shah, MD, Anthony R. Mato, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2015) 126 (23): 5003.

https://doi.org/10.1182/blood.V126.23.5003.5003

Published: 2015

Journal Articles

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study

David M. Hyman, MD, Eli Diamond, Vivek Subbiah, MD, Jean-Yves Blay, MD PhD, A. Craig Lockhart, Omar Abdel-Wahab, MD, Florin Sirzen, Maria Luisa Veronese, MD, Susan Frances Laserre, Elena Elez, Jose Baselga, MD PhD

Blood (2014) 124 (21): 635.

https://doi.org/10.1182/blood.V124.21.635.635

Published: 2014

Journal Articles

Evaluating the Need for Anticoagulation Beyond 6 Months for Patients with Cancer-Associated Venous Thromboembolism: A Retrospect of Real Life (EXTEND Study)

Martha L Louzada, BSc, MD MSc, Michael J. Kovacs, MD FRCPC, Fatimah Al-ani, MD, Lenicio Siqueira, Alejandro Lazo-Langner, MD MSc

Blood (2014) 124 (21): 4245.

https://doi.org/10.1182/blood.V124.21.4245.4245

Published: 2014

Journal Articles

Assessment of Risk of Thromboprophylaxis Failure in Hospitalized Patients with Cancer (Artic Study)

Martha L Louzada, BSc, MD MSc, Michael J. Kovacs, MD, FAtimah Al-Ani, MD, Alejandro Lazo-Langner, MD MSc, Lenicio Siqueira

Blood (2014) 124 (21): 588.

https://doi.org/10.1182/blood.V124.21.588.588

Published: 2014

Journal Articles

Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients

Shahrukh K Hashmi, MD, Daniel Wojenski, Pharm.D R.Ph, Gabriel Bartoo, Pharm.D R.Ph, Julianna A. Merten, Pharm.D., Ross Dierkhising, M.S., Rokea Elazhary, MD PhD, John W Wilson, MD, Robert Wolf, Pharm.D., Mrinal M. Patnaik, MBBS, William Hogan, MD, Mark R. Litzow, MD

Blood (2013) 122 (21): 916.

https://doi.org/10.1182/blood.V122.21.916.916

Published: 2013

Journal Articles

Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Pier Luigi Zinzani, MD, Julie M Vose, MD, MBA, Myron S. Czuczman, MD, Craig Reeder, MD, Corinne Haioun, MD, Jonathan Polikoff, MD, Herve Tilly, Dennis Pietronigro, Annette Ervin-Haynes, Ju Li, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2738.

https://doi.org/10.1182/blood.V120.21.2738.2738

Published: 2012

Journal Articles

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Christine Chen, MD, Harminder Paul, Trina Wang, RN, Lisa W Le, MSc, Vishal Kukreti, MD, Ellen Nong Wei, Anthea Lau, P. Leif Bergsagel, MD, Nimisha Dave, Suzanne Trudel, MD

Blood (2012) 120 (21): 718.

https://doi.org/10.1182/blood.V120.21.718.718

Published: 2012

Journal Articles

The Clinical Course of Head and Neck Cancer in Patients with Chronic Lymphocytic Leukemia

Aaron D Maybury, Ephraim P. Hochberg, MD, Lori J Wirth, MD, Jeremy S. Abramson, MD, Kevin S Emerick, MD, James S. Michaelson, PhD, Christiana E. Toomey, Kristina Cibor, Brad Diephuis, Devon Bush

Blood (2011) 118 (21): 4741.

https://doi.org/10.1182/blood.V118.21.4741.4741

Published: 2011

Journal Articles

Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced

Avichai Shimoni, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler

Blood (2011) 118 (21): 655.

https://doi.org/10.1182/blood.V118.21.655.655

Published: 2011

Journal Articles

Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation.

M. Mansour Ceesay, MRCPath, ZiYi Lim, MRCPath, Michelle Kenyon, Aloysius Y.L. Ho, FRCPath, Stephen Devereux, FRCPath, Steve Schey, FRCPath, Aleksandar Mijovic, FRCPath, Antonio Pagliuca, FRCPath, Ghulam J. Mufti, FRCPath

Blood (2007) 110 (11): 1665.

https://doi.org/10.1182/blood.V110.11.1665.1665

Published: 2007

Journal Articles

Casein Kinase II Inhibition in MEG-01 Cell Line Results in Apoptosis, Megakaryocytopoiesis and Functional Platelets Release.

Alieta Ciocea, BS, Natalya V. Narizhneva, PhD, Evrim Erdogan, BS, Tatiana V. Byzova, PhD, Michael Kalafatis, PhD

Blood (2005) 106 (11): 4328.

https://doi.org/10.1182/blood.V106.11.4328.4328

Published: 2005

Journal Articles

Aggressive Cutaneous Squamous Cell Carcinoma (SCC) in Chronic Lymphocytic Leukaemia (CLL).

Steven W. Lane, MBBS, Peter N. Mollee, MBBS MMedSc, Robert Bird, MBBS, Sandro Porceddu, MBBS, Devinder Gill, MBBS

Blood (2005) 106 (11): 4993.

https://doi.org/10.1182/blood.V106.11.4993.4993

Published: 2005

Journal Articles

Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.

Genevieve Gallagher, MD, Donna E. Hogge, MD, Thomas J. Nevill, MD, Stephen H. Nantel, MD, Michael J. Barnett, MD, John D. Shepherd, MD, Heather J. Sutherland, MD, Cynthia L. Toze, MD, Clayton A. Smith, MD, Julye C. Lavoie, MD, Kevin W. Song, MD, Donna L. Forrest, MD

Blood (2005) 106 (11): 1120.

https://doi.org/10.1182/blood.V106.11.1120.1120

Published: 2005

Journal Articles

Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.

Chitra Hosing, MD, Rima M. Saliba, PhD, Marcos De Lima, MD, Sergio Giralt, MD, Shubhra Ghosh, MD, Yvonne Hsu, Paolo Anderlini, MD, Sharon R. Hymes, MD, Borje Andersson, MD, Issa F. Khouri, MD, Richard Champlin, MD, Daniel Couriel, MD

Blood (2005) 106 (11): 1123.

https://doi.org/10.1182/blood.V106.11.1123.1123

Published: 2005

NARROW

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Risk of Non-Melanoma Skin Cancer Following Hematopoietic Cell Transplantation and Voriconazole-Associated Risk

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients

Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study

Evaluating the Need for Anticoagulation Beyond 6 Months for Patients with Cancer-Associated Venous Thromboembolism: A Retrospect of Real Life (EXTEND Study)

Assessment of Risk of Thromboprophylaxis Failure in Hospitalized Patients with Cancer (Artic Study)

Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients

Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

The Clinical Course of Head and Neck Cancer in Patients with Chronic Lymphocytic Leukemia

Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced

Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation.

Casein Kinase II Inhibition in MEG-01 Cell Line Results in Apoptosis, Megakaryocytopoiesis and Functional Platelets Release.

Aggressive Cutaneous Squamous Cell Carcinoma (SCC) in Chronic Lymphocytic Leukaemia (CLL).

Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.

Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only